Summary
Guardant Health, Inc. reported its third-quarter 2024 financial results, showcasing robust revenue growth driven by its precision oncology testing segment. Total revenue increased by 34% year-over-year to $191.5 million, with precision oncology testing revenue growing by 35% to $180.6 million. This growth was fueled by both increased test volumes from clinical customers and biopharmaceutical clients, along with improved reimbursement rates, particularly for the Guardant360 LDT test. Despite strong top-line performance, the company continues to operate at a net loss, reporting a loss of $107.8 million for the quarter. The company maintains a healthy liquidity position with approximately $1.0 billion in cash, cash equivalents, and marketable debt securities as of September 30, 2024, providing runway for continued investment in research and development and commercial expansion. A significant development during the quarter was the achievement of performance metrics for certain performance-based restricted stock units (PSUs), leading to a cumulative charge of $23.5 million in stock-based compensation expense. While R&D expenses saw a slight decrease year-over-year, sales and marketing expenses increased significantly due to commercial team build-out and marketing efforts for product launches, including the Shield test. The company also noted progress in its intellectual property disputes and continues to advance its product pipeline and international expansion efforts.
Financial Highlights
53 data points| Revenue | $191.48M |
| Cost of Revenue | $74.49M |
| Gross Profit | $116.99M |
| R&D Expenses | $87.31M |
| Operating Expenses | $308.80M |
| Operating Income | -$117.33M |
| Interest Expense | $645K |
| Net Income | -$107.75M |
| EPS (Basic) | $-0.88 |
| EPS (Diluted) | $-0.88 |
| Shares Outstanding (Basic) | 123.05M |
| Shares Outstanding (Diluted) | 123.05M |
Key Highlights
- 1Total revenue for the third quarter of 2024 increased by 34% to $191.5 million, compared to $143.0 million in the prior year period.
- 2Precision oncology testing revenue rose by 35% to $180.6 million, driven by higher test volumes and improved reimbursement, notably for the Guardant360 LDT test.
- 3Net loss for the quarter was $107.8 million, a slight increase from $86.1 million in Q3 2023, reflecting continued investment in growth initiatives.
- 4The company ended the quarter with a strong liquidity position, holding $1.0 billion in cash, cash equivalents, and marketable debt securities.
- 5Sales and marketing expenses increased by 42% to $97.9 million, reflecting investments in commercial team expansion and marketing for product launches.
- 6Research and development expenses decreased by 7% to $87.3 million, primarily due to lower clinical study costs as the ECLIPSE study nears completion.
- 7Guardant Health is actively managing legal proceedings, including a patent infringement suit against Tempus AI, Inc. and a false advertising dispute with Natera, Inc.